Testosterone therapy randomized controlled trials exhibit suboptimal reporting of adverse events, including polycythemia, gynecomastia, major adverse cardiovascular events, and obstructive sleep apnea
A critical analysis of 30 testosterone therapy (TTh) randomized controlled trials found highly heterogeneous and suboptimal reporting of adverse events. Only 83% measured hematocrit levels, 23% reported baseline values, 17% reported gynecomastia, 20% reported MACE, and 33% mentioned OSA, with few reporting incidence rates. This underscores the need for standardization in TTh trials.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Testosterone therapy randomized controlled trials exhibit suboptimal reporting of adverse events, including polycythemia, gynecomastia, major adverse cardiovascular events, and obstructive sleep apnea The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 47/100 (low).
The Claim
Testosterone therapy randomized controlled trials exhibit suboptimal reporting of adverse events, including polycythemia, gynecomastia, major adverse cardiovascular events, and obstructive sleep apnea
This conclusion is most relevant to: Men enrolled in testosterone therapy randomized controlled trials (excluding female and animal studies).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸A critical analysis of the quality of testosterone therapy randomized controlled trials. (Sexual medicine reviews, 2026) —
How It Works
The proposed biological pathway:
- ▸TTh trials were identified via PubMed search
- ▸Trials were assessed for sample size, duration, testosterone levels, and adverse event definitions
- ▸Rates of PCT, GYN, MACE, and OSA were extracted
- ▸Analysis revealed suboptimal and heterogeneous reporting of adverse events
Who Might Benefit
Evidence fit by population:
- ▸Men enrolled in testosterone therapy randomized controlled trials (excluding female and animal studies)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Analysis based on published abstracts and trial reports, which may not capture all details
- ▸Heterogeneity in adverse event definitions across trials limits comparability
- ▸Only 30 trials met inclusion criteria, potentially limiting generalizability
Frequently Asked Questions
What percentage of testosterone therapy RCTs reported baseline hematocrit levels?▼
Only 23% of the included RCTs reported baseline hematocrit values, with a median baseline of 43% and on-treatment median of 45%.
How many testosterone therapy RCTs reported major adverse cardiovascular events (MACE)?▼
Only 20% of the trials reported MACE, and the definitions varied across studies.
What was the median sample size and follow-up duration in the analyzed testosterone therapy RCTs?▼
The median sample size was 76 participants, and the median follow-up was 8 months.
Why is standardization needed in testosterone therapy trials?▼
The analysis found suboptimal and heterogeneous reporting of adverse events, such as gynecomastia and obstructive sleep apnea, which hampers accurate assessment of safety and necessitates standardized reporting guidelines.
References
- 1.Furtado TP, Novaes LF, Flores JM, Mulhall JP. “A critical analysis of the quality of testosterone therapy randomized controlled trials..” Sexual medicine reviews, 2026. PMID: 42636349 DOI: 10.1093/sxmrev/qeag064